Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific, SPT Labtech to Comarket Sequencing Library Prep Products

NEW YORK – SPT Labtech of Cambridge, UK, said on Tuesday that it has signed an agreement with Thermo Fisher Scientific to comarket the firms' products for next-generation sequencing sample preparation.

Under the initiative, the companies will comarket Thermo Fisher's NGS library preparation kits with SPT Labtech's Mosquito HV Genomics and Dragonfly Discovery automation systems, which they said will result in reduced reagent volumes.

The deal will initially support Thermo Fisher's Invitrogen Collibri DNA Library Prep Kits for Illumina systems and Collibri Library Quantification Kits for use in infectious disease studies.

"NGS technology evolves quickly and it can be time consuming for individual labs to automate the newest library prep kits," said Joby Jenkins, director of product strategy at SPT Labtech, in a statement. "Our goal is to automate and miniaturize processes for NGS so scientists can expand the scope of their research programs and, ultimately, generate insights into human health."

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.